An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.
- Ades, F
- Senterre, Christelle
- Zardavas, Dimitros
- De Azambuja, Evandro
- Popescu, Razvan
- Parent, Florence
- Piccart-Gebhart, Martine
Publication date
December 2014
DOI Publisher
Elsevier BV ISSN
0959-8049 Citation count (estimate)
6Abstract
The European Union (EU) has adopted a common procedure for granting marketing authorisation for cancer drugs. Nevertheless, pricing and reimbursement decisions are a competency of EU national governments, and their policies are diverse. We aimed to evaluate the time for trastuzumab reimbursement approval and its association to health expenditure, to health policy performance, to the availability of cost-effectiveness studies and to breast cancer outcome.SCOPUS: ar.jinfo:eu-repo/semantics/publishe
Add to ORKG